PIK3CA and breast cancer: Seven of our included nine RCTs provided ORR efficacy data, and significant differences were found, indicating that the application of PI3K inhibitors may benefit overall BC patients (OR = 1.539, 95% CI: 1.074 to 2.204); there was substantial heterogeneity in this outcome (p = 0.015, I2 = 54.6%).